✦ LIBER ✦

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

✍ Scribed by Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Christophe Goffard; Adriano Lazzarin; Andrej Wöhrmann; Christine Katlama; Timothy Wilkin; Richard Haubrich; Calvin Cohen; Charles Farthing; Dushyantha Jayaweera; Martin Markowitz; Peter Ruane; Sabrina Spinosa-Guzman; Eric Lefebvre

Book ID: 117300919
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 180 KB
Volume: 369
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)60497-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of darunavir-ritonav

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

✍ José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banheg 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lal 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christi 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Durable efficacy of tipranavir-ritonavir

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

✍ Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlam 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 124 KB